Objective To investigate the clinical effect of butylphthalide combined with edaravone in the treatment of progressive cerebral infarction and its impact on neurological deficits and hemorheology .Methods 78 patients with progressive cerebral infarction were divided into the control group and observation group according to the random number table ,39 cases in each group .The two groups were given conventional treatment ,the control group was given edaravone on the basis of the conventional treatment ,while the observation group was given butylphthalide soft capsules and edaravone .All of the patients were given continuous medication for 12d.The degree of neurological deficit score,clinical assessment efficacy and adverse reactions were compared between the two groups .Results The total effective rate of the observation group was 89.74%,which was significantly higher than 66.67% of the control group(χ2 =11.672,P<0.05).After treatment,the NIHSS scores were decreased significantly (t=11.04,12.88,all P<0.05),that in the observation group was declined more significantly ,compared with the control group ,the differ-ence was statistically significant (t=10.93,P<0.05).After treatment,the fibrin level,blood viscosity and platelet aggregation of the observation group were significantly lower than those of the control group ( t=6.69,6.22,7.30,all P<0.05).Conclusion Butylphthalide combined with edaravone in the treatment of progressive cerebral infarction can significantly improve the patients'neurological symptoms ,reduce fibrin level ,blood viscosity and platelet aggrega-tion,and its security is good ,which is worth to be applied in clinical .